Credit Suisse analyst Geoffrey Weiner initiated coverage of Exelixis with an Outperform rating and $29 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL:
- William Blair says Exelixis cabozantinib patent verdict in line with expectation
- Court Rulings Bring Good and Bad News for Exelixis (NASDAQ:EXEL)
- Exelixis receives favorable ruling in patent litigation with MSN Laboratories
- Exelixis, Ajinomoto enter license agreement
- Exelixis price target lowered to $20 from $21 at Cowen